Recombinant expression and neutralizing activity of an MHC class II binding epitope of toxic shock syndrome toxin-1

Vaccine

Volumn 18, Issue 21, 2000, Pages 2312-2320

  Rubinchik, Evelina ^a   Chow, Anthony W ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Dept Earth Ocean Sci Univ B   (Canada)

Author keywords

Superantigen recombinant vaccine; Toxic shock; Toxins

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; SUPERANTIGEN; TOXIN;

ANIMAL CELL; ANTIGEN PRESENTING CELL; ANTIGENICITY; ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; EPITOPE MAPPING; MAJOR HISTOCOMPATIBILITY COMPLEX; MITOGENESIS; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RECEPTOR BINDING; TARGET CELL; TOXIC SHOCK SYNDROME;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL TOXINS; BINDING SITES; ENTEROTOXINS; EPITOPES; GLUTATHIONE TRANSFERASE; HUMANS; IMMUNE SERA; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; RECOMBINANT FUSION PROTEINS; STAPHYLOCOCCUS AUREUS; SUPERANTIGENS; TUMOR NECROSIS FACTOR-ALPHA; VACCINES, SYNTHETIC;

EID: 0034104550     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00554-X     Document Type: Article

References (36)

1. Bohach G.A., Fast D.J., Nelson R.D., Schlievert P.M. Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illness. CRC Crit. Rev. Microbiol. 17:1990;251-272.
2. Kotzin B.L., Leung D.Y.M., Kappler J., Marrack P. Superantigens and their potential role in human disease. Adv. Immun. 54:1993;99-166.
3. Labrecque N., Thibodeau J., Sekaly R.-P. Interactions between staphylococcal superantigens and MHC class II molecules. Semin. Immun. 5:1993;23-32.
4. Karp D.R., Teletski C.L., Scholl P.R., Geha R., Long E.O. The α-1 domain of the HLA-DR molecule is essential for the high-affinity binding of the toxic shock syndrome toxin-1. Nature. 346:1990;474-476.
5. Poindexter N.J., Schlievert P.M. Toxic-shock-syndrome toxin 1-induced proliferation of lymphocytes: comparison of the mitogenic response of human, murine, and rabbit lymphocytes. J. Infect. Dis. 151:1985;65-72.
6. Jupin C., Anderson S., Damais C., Alouf J.E., Parant M. Toxic shock syndrome toxin 1 as an inducer of human tumor necrosis factors and gamma interferon. J. Exp. Med. 167:1988;752-761.
7. Kum W.W.S., Laupland K.B., See R.H., Chow A.W. Improved purification and biologic activities of staphylococcal toxic shock syndrome toxin 1. J. Clin. Microbiol. 31:1993;2654-2660.
8. Parsonnet J. Mediators in the pathogenesis of TSS: overview. Rev. Infect. Dis. 11:(Suppl 1):1989;S263-S269.
9. See R.H., Kum W.W.S., Chang A.H., Goh S.H., Chow A.W. Activation of human monocytes for IL-1β and TNFα secretion by staphylococcal toxic shock syndrome toxin-1 requires direct cell contact with T lymphocytes. Mollby R., Flock J.-I., Nord C.F., Christensson B. The Staphylococci, Proceedings of the VIIth International Symposium on Staphylococci and Staphylococcal Infections, Stockholm, 1992. 1994;443-445 Fischer, Stuttgart.
10. Kum WWS, Laupland KB, Chow AW, Defining a novel domain of staphylococcal toxic shock syndrome toxin-1 critical for major histocompatibility complex class II binding, superantigenic activity, and lethality, Can. J. Microbiol. 2000;46:171-179.
11. Hoffmann M.L., Jablonski L.M., Crum K.K., Hackett S.P., Chi Y., Stauffacher C.V., Stevens D.L., Bohach G.A. Predictions of T-cell receptor- and major histocompatibility complex-binding sites on staphylcoccal enterotoxin C1. Infect. Immun. 62:1994;3396-3407.
12. Monera O.D., Zhou N.E., Kay C.M., Hodges R.S. Comparison of antiparallel and parallel two-stranded α-helical coiled-coils. Design, synthesis and characterization. J. Biol. Chem. 265:1993;19,218-19,227.
13. Smith D.B., Johnson K.S. Single-step purification of peptides expressed in Escherichia Coli as fusions with glutathione-S-transferase. Gene. 67:1988;31-40.
14. Scott J.K., Smith G.P. Searching for peptide ligands with an epitope library. Science. 249:1990;386-390.
15. Sambrook J., Fritsch E.F., Maniatis T. Molecular Cloning, A Laboratory Manual. 2nd ed. 1989;Cold Spring Harbor Laboratory Press, New York.
16. Lin T.C., Webster R.E., Konigsbers W. Isolation and characterization of the C and D proteins coded by gene IX and gene VI in the filamentous bacteriophage fl and fd. J. Biol. Chem. 255:1980;10,331-10,337.
17. Wong R.S.Y., Jost H., Hancock R.E.W. Link-insertion mutagenesis of Pseudomonas aeruginosa outer membrane protein OprF. Mol. Microbiol. 10:1993;283-292.
18. Wong R.S.Y., Wirtz R.A., Hancock R.E.W. Pseudomonas aeruginosa outer membrane protein OprF as an expression vector for foreign epitopes: the effects of positioning and length on the antigenicity of the epitope. Gene. 158:1995;55-60.
19. Finnen R.L., Martin N.L., Siehnel R.J., Woodruff W.A., Rosok M., Hancock R.E.W. Analysis of the Pseudomonas aeruginosa major outer membrane protein OprF by use of truncated OprF derivatives and monoclonal antibodies. J. Bacteriol. 174:1992;4977-4985.
20. Rosten P.M., Bartlett K.H., Chow A.W. Serologic responses to toxic shock syndrome toxin 1 in menstrual and nonmenstrual TSS. Clin. Invest. Med. 11:1988;187-192.
21. See R.H., Kum W.W.S., Chang A.H., Goh S.H., Chow A.W. Induction of tumor necrosis factor and interleukin-1 by purified staphylococcal toxic shock syndrome toxin 1 requires the presence of both monocytes and T lymphocytes. Infect. Immun. 60:1992;2612-2618.
22. Palaszynski E.W., Ihle J.N. Evidence for specific receptors for interleukin 3 on lymphokine- dependent cell lines established from long-term bone marrow cultures. J. Immun. 132:1984;1872-1879.
23. See R.H., Krystal G., Chow A.W. Binding competition of toxic shock syndrome toxin 1 and other staphylococcal exoproteins for receptors on human peripheral blood mononuclear cells. Infect. Immun. 58:1990;2392-2396.
24. Kain K.C., Schulzer M., Chow A.W. Clinical spectrum of nonmenstrual toxic shock syndrome (TSS): comparison with menstrual TSS by multivariate discriminant analyses. Clin. Infect. Dis. 16:1993;100-106.
25. Bavari S., Dyas B., Ulrich R.G. Superantigen vaccines: A comparative study of genetically attenuated receptor-binding mutants of staphylococcal enterotoxin A. J. Infect. Dis. 174:1996;338-345.
26. Lowell G.H., Colleton C., Frost D., Kaminski R.W., Hughes M., Hatch J., et al. Immunogenicity and efficacy against lethal aerosol staphylococcal enterotoxin B challenge in monkeys by intramuscular and respiratory delivery of proteosome-toxoid vaccines. Infect. Immun. 64:1996;4686-4693.
27. Poindexter N.J., Schlievert P.M. Suppression of immunoglobulin-secreting cells from human peripheral blood by toxic-shock-syndrome toxin-1. J. Infect. Dis. 153:1986;772-779.
28. Donnelly R.P., Rogers T.J. Immunosuppression induced by staphylococcal enterotoxin B. Cell. Immun. 72:1982;166-177.
29. Arnon R., Horwitz R.J. Synthetic peptides as vaccines. Curr. Opin. Immun. 4:1992;449-452.
30. Greenwood J., Willis A.E., Perham R.N. Multiple display of foreign peptides on a filamentous bacteriophage: peptides from Plasmodium falciparum circumsporozoite protein as antigens. J. Molec. Biol. 220:1991;821-827.
31. Cruz V.F., Lal A.A., McCutchan T.F. Immunogenicity and epitope mapping of foreign sequences via genetically engineered filamentous phage. J. Biol. Chem. 263:1987;4318-4322.
32. Johnson K.S., Harrison G.B.L., Lightowlers M.W., O'Hoy K.L., Cougle W.G., Dempster R.P., Lawrence S.B., Vinton J.G., Heath D.D., Rickard M.D. Vaccination against ovine cysticercosis using a defined recombinant antigen. Nature. 338:1989;585-587.
33. Wysocki L., Manser T., Gefter M.L. Somatic evaluation of variable region structures during an immune response. Proc. Natl. Acad. Sci. USA. 83:1986;1847-1851.
34. Vieira P., Rajewsky K. The half-lives of serum immunoglobulins in adult mice. Eur. J. Immun. 18:1988;313-316.
35. Leclerc C., Charbi A., Martineau P., Deriard E., Hofnung H. The cellular location of a foreign B cell epitope expressed by recombinant bacteria determines its T cell-independent or T cell-dependent characteristics. J. Immun. 144:1993;3174-3182.
36. Hancock R.E.W., Carey A.M. Outer membrane of Pseudomonas aeruginosa: heat-2-mercaptoethanol-modifiable proteins. J. Bacteriol. 140:1979;902-910.